This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Lilly (LLY) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Is Nektar (NKTR) Up 11.2% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Endo (ENDP) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Endo (ENDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Health Care ETFs Outperforming XLV on YTD Basis
by Zacks Equity Research
Health care ETFs provide handsome returns year to date.
Is Nektar Therapeutics (NKTR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NKTR) Outperforming Other Medical Stocks This Year?
High Beta, Momentum ETFs & Stocks to Trade in a Market Rally
by Sweta Killa
While the rally seems to be broad-based, high beta and high momentum products are expected to lead the market.
Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y
by Zacks Equity Research
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
Nektar Therapeutics (NKTR) Q2 Earnings Meet Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 0.00% and 4.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Nektar Therapeutics (NKTR) Might Surprise This Earnings Season
by Zacks Equity Research
Nektar Therapeutics (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Is a Beat in the Cards for Nektar (NKTR) in Q2 Earnings?
by Zacks Equity Research
Nektar Therapeutics (NKTR) is likely to beat estimates when it reports second-quarter results. Investors are expected to focus on pipeline progress.
Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the second quarter. Eliquis and Opdivo continue to record solid sales.
Nektar Therapeutics (NKTR) Jumps: Stock Rises 6.5%
by Zacks Equity Research
Nektar Therapeutics (NKTR) shares rose nearly 7% in the last trading session, amid huge volumes.
Company News For Jun 5, 2018
by Zacks Equity Research
Companies in the news are: GHDX,BAYN.DE, NKTR,DCPH
Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study
by Zacks Equity Research
Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.
Is the Options Market Predicting a Spike in Nektar (NKTR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Nektar (NKTR) stock based on the movements in the options market lately.
Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate
by Zacks Equity Research
Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.
Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y
by Zacks Equity Research
Nektar (NKTR) reports wider-than-expected loss in Q1 while revenues rise substantially year over year. It collaborates with Bristol-Myers for advancing immuno-oncology and immunology pipeline.
Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.
Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for VIOG
Nektar Starts Phase I/II Combo for Advanced Solid Tumors
by Zacks Equity Research
Nektar (NKTR) initiates dosing in a phase I/II study, evaluating the combination of its two novel immuno-oncology agents, NKTR-262 and NKTR-214, on patients with advanced solid tumors.
Nektar (NKTR) Q4 Loss Narrower Than Expected, Sales Soar Y/Y
by Zacks Equity Research
Nektar (NKTR) reports narrower-than-expected loss in Q4. Revenues substantially rise year over year owing to massive increase in license and collaboration fees.
Why Nektar (NKTR) Might Surprise This Earnings Season
by Zacks Equity Research
Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.